CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the update, the company plans to open its clinical sites in Italy imminently in addition to the previously opened 41 clinical trial sites of the 60 selected across the U.S., France, Spain, and Switzerland. “Our team has continued to make dedicated efforts to build momentum and drive patient enrollment in this important clinical trial. We are incredibly pleased to add Italy to our growing portfolio of European countries for this global study,” said John Climaco, CEO of CNS Pharmaceuticals. “Our team continues to focus on bringing additional clinical trial sites online to further accelerate our patient enrollment and our advance toward our planned interim analysis, which we expect in the third quarter of 2023. We look forward to getting sites up and running in Italy in the near future. We remain dedicated to advancing Berubicin and potentially addressing the unmet need in the treatment of GBM.”
To view the full press release, visit https://ibn.fm/K4Tr5
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
